<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Alemtuzumab is effective in reducing the risk of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) after allogeneic stem cell transplantation (ASCT) </plain></SENT>
<SENT sid="1" pm="."><plain>Alemtuzumab may also delay immune reconstitution and reduce graft-versus-<z:hpo ids='HP_0001909'>leukemia</z:hpo> effects </plain></SENT>
<SENT sid="2" pm="."><plain>The optimal dose has not been established </plain></SENT>
<SENT sid="3" pm="."><plain>We investigated engraftment, <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD incidence and severity, and pharmacokinetics of alemtuzumab associated with the use of low-dose alemtuzumab/<z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>/total body irradiation and ASCT for patients with aggressive CD52-positive <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo>, 12 patients were treated </plain></SENT>
<SENT sid="5" pm="."><plain>Alemtuzumab 10 mg daily on days -7 to -3 was given intravenously </plain></SENT>
<SENT sid="6" pm="."><plain>Tacrolimus and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> were used for GVHD prophylaxis </plain></SENT>
<SENT sid="7" pm="."><plain>Alemtuzemab was not detected in any of the 36 sequential serum samples tested between days -1 and +21 of transplant </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients engrafted rapidly; the median time to an absolute neutrophil count &gt;0.5 x 10(9)/l was 14 days (range 11-17 days), and the median time to a platelet count &gt;20 x 10(9)/l was 16 days (range 6-30 days) </plain></SENT>
<SENT sid="9" pm="."><plain>By 1 month after transplant, nine patients had 100% donor chimerism, while three had mixed donor chimerism </plain></SENT>
<SENT sid="10" pm="."><plain>At 3 months, 11 had achieved 100% donor chimerism </plain></SENT>
<SENT sid="11" pm="."><plain>No cases of grade III/IV <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD occurred </plain></SENT>
<SENT sid="12" pm="."><plain>At a median follow-up interval of 14.7 months (range 4-24), seven patients remained alive, and five remained free of disease </plain></SENT>
</text></document>